Brent Saunders, Bausch + Lomb CEO (Richard Drew/AP Images)
May 18, 2023 03:28 PM EDTUpdated 03:59 PM
Pharma
FDA+

Bausch + Lomb and No­valiq win ap­proval for dry eye dis­ease treat­ment

Nicole DeFeudis

Editor

Bausch + Lomb and No­valiq se­cured an ap­proval for their dry eye dis­ease drop on Thurs­day, to be mar­ket­ed as Miebo.

The drug, al­so known as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Genen­tech vet launch­es ADC start­up with $20M

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times